Pfizer Furnishes Reaffirmed Fiscal Year 2026 Guidance
Summary
Pfizer, following its Chief Financial Officer transition announcement on June 18, 2026, is reaffirming its full-year 2026 guidance. This guidance was initially introduced on December 16, 2025, and previously reaffirmed on May 5, 2026. The company reiterates its projected Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.
Why It Matters
Investors should note Pfizer's reaffirmation of its full-year 2026 guidance, including revenue and EPS ranges, despite a recent CFO transition. This signals stability in the company's financial outlook.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how PFE traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View PFE Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“The company is reaffirming all components of its full-year 2026 guidance previously announced, including Revenues in a range of $59.”
— From Item 7.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000078003
- Filing Date
- Thursday, June 18, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- medium
- Sentiment
- positive